Leerink Swann Reaffirms Buy Rating for Sanofi (SNY)
Sanofi (NYSE:SNY)‘s stock had its “buy” rating reiterated by equities research analysts at Leerink Swann in a report issued on Sunday.
Several other research firms have also issued reports on SNY. Berenberg Bank upgraded Sanofi from a “hold” rating to a “buy” rating in a research report on Thursday, September 8th. Piper Jaffray Cos. started coverage on Sanofi in a research note on Friday, September 23rd. They set a “neutral” rating on the stock. BNP Paribas raised Sanofi from an “underperform” rating to a “neutral” rating in a research note on Tuesday, September 13th. TheStreet downgraded Sanofi from a “buy” rating to a “hold” rating in a research note on Monday, August 22nd. Finally, JPMorgan Chase & Co. reaffirmed an “underweight” rating on shares of Sanofi in a research note on Thursday, September 15th. Three research analysts have rated the stock with a sell rating, nine have given a hold rating and five have assigned a buy rating to the stock. Sanofi has an average rating of “Hold” and a consensus price target of $60.50.
Sanofi (NYSE:SNY) opened at 38.53 on Friday. The firm has a 50-day moving average price of $38.79 and a 200-day moving average price of $40.45. Sanofi has a 52 week low of $37.41 and a 52 week high of $51.88. The stock has a market cap of $99.18 billion, a P/E ratio of 21.36 and a beta of 0.98.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/09/leerink-swann-reaffirms-buy-rating-for-sanofi-sny-2.html
Hedge funds have recently added to or reduced their stakes in the stock. Hamlin Capital Management LLC bought a new stake in Sanofi during the second quarter worth about $56,725,000. Aviance Capital Management LLC increased its stake in Sanofi by 113.7% in the second quarter. Aviance Capital Management LLC now owns 462,941 shares of the company’s stock worth $19,374,000 after buying an additional 246,323 shares in the last quarter. FineMark National Bank & Trust increased its stake in Sanofi by 23.2% in the second quarter. FineMark National Bank & Trust now owns 10,231 shares of the company’s stock worth $428,000 after buying an additional 1,926 shares in the last quarter. First Manhattan Co. increased its stake in Sanofi by 0.6% in the second quarter. First Manhattan Co. now owns 19,281 shares of the company’s stock worth $806,000 after buying an additional 113 shares in the last quarter. Finally, Managed Asset Portfolios LLC increased its stake in Sanofi by 4.4% in the first quarter. Managed Asset Portfolios LLC now owns 234,110 shares of the company’s stock worth $9,402,000 after buying an additional 9,945 shares in the last quarter. 9.42% of the stock is currently owned by institutional investors and hedge funds.
Sanofi, formerly Sanofi-Aventis, is a healthcare company engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company operates through three segments: Pharmaceuticals, Human Vaccines (Vaccines) and Animal Health. The Pharmaceuticals segment consists of research, development, production and marketing of medicines, including those originating from Genzyme Corporation.
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.